Cryptotanshinone is a candidate therapeutic agent for interstitial lung disease associated with a BRICHOS-domain mutation of SFTPC
Motoyasu Hosokawa(Kyoto University), Masatoshi Hagiwara(Kyoto University)
Cited by 5
Related Papers
Selective inhibition of the kinase DYRK1A by targeting its folding process
|Nature Communications|2016|87
CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses
|Journal of Clinical Investigation|2014|77
A Novel Dual Specificity Phosphatase SKRP1 Interacts with the MAPK Kinase MKK7 and Inactivates the JNK MAPK Pathway
|Journal of Biological Chemistry|2002|47
Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ
|Scientific Reports|2015|38
Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer
|Science Translational Medicine|2022|33